secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001193125-24-233038
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA to present Phase 1 expansion data for IDE397 in MTAP-deletion NSCLC/urothelial at EORTC-NCI-AACR
--------------------------------------------------------------------------------

- Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.
- Presenter is Dr. Benjamin Herzberg, Columbia University; abstract #501 LBA.
- Additional poster: preclinical data for MAT2A + PRMT5 combination in MTAP-deleted tumors (poster PB204).
- Additional poster: preclinical data for IDE161, a PARG inhibitor targeting solid tumors (poster PB337).
- EORTC-NCI-AACR Symposium in Barcelona, Oct 23-25, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312524233038/0001193125-24-233038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312524233038/d828798d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-233038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer